Prosecution Insights
Last updated: November 20, 2026

Amy M Bunker, USPTO Patent Examiner

Listed by the USPTO as BUNKER, AMY M

Tech Center 1600 • Art Units: 1612 1625 1634 1639 1675 1684

This examiner grants 29% of resolved cases

Analysis

This examiner is in Tech Center 1600 and Art Unit 1612, with 514 resolved cases. The allowance rate is 29.0%, and the median time to allowance is 1427 days. The 45.1% interview lift is a strong positive signal against a low overall allowance rate, indicating that interviews may be especially useful when substantive issues are clearly framed.

The principal companies are The Regents of the University of California, Bio-Rad Laboratories Inc., and University of Washington. The leading firms are DAMBROSIO & MENON, P.L.L.C., Jones Day, and LEYDIG VOIT & MAYER, LTD. Practitioners should expect a demanding record but may improve case positioning by using interviews alongside technically supported amendments and evidence.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

29.0%
Allow Rate
-31.0% vs TC avg
578
Total Applications
+45.1%
Interview Lift
1427
Avg Prosecution Days
Based on 514 resolved cases, 2023–2026

Rejection Statute Breakdown

6.7%
§101 Eligibility
19.3%
§102 Novelty
36.5%
§103 Obviousness
27.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18657366 Methods of Producing Size-Selected Nucleic Acid Libraries and Compositions and Kits for Practicing Same Non-Final OA The Regents of the University of California
17911509 SINGLE-CELL COMBINATORIAL INDEXED CYTOMETRY SEQUENCING Final Rejection The Regents of the University of California
18235015 FC-RECEPTOR BASED AFFINITY CHROMATOGRAPHY Non-Final OA Hoffmann-La Roche Inc.
18550004 HIGH THROUGHOUT SCREENING IN DROPLETS Final Rejection Novartis AG
17938254 Polynucleotide Barcodes for Multiplexed Proteomics Final Rejection Singular Genomics Systems, Inc.
18256877 METHODS FOR SEQUENCING POLYNUCLEOTIDE FRAGMENTS FROM BOTH ENDS Final Rejection Agilent Technologies, Inc.
18374492 MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC Final Rejection Regeneron Pharmaceuticals, Inc.
16936197 FUNCTIONALIZED SOLID SUPPORT Non-Final OA Massachusetts Institute of Technology
18235205 HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS Non-Final OA LIFE TECHNOLOGIES CORPORATION
18297137 METHODS AND COMPOSITIONS FOR ANALYZING ANTIGEN BINDING MOLECULES Non-Final OA 10x Genomics, Inc.
18035269 METHODS FOR IDENTIFYING DRIVERS OF IMMUNE RESPONSES USING MOLECULAR EXPRESSION SIGNATURES OF IMMUNOMODULATING AGENTS Final Rejection The General Hospital Corporation
17785762 NUCLEIC ACID ANALYSIS METHODS AND APPARATUS Non-Final OA BASF SE
18381400 METHODS AND COMPOSITIONS FOR TRACKING BARCODES IN PARTITIONS Non-Final OA Bio-Rad Laboratories, Inc.
17729760 SYSTEM AND METHOD FOR ISOLATING AND ANALYZING CELLS Non-Final OA Bio-Rad Laboratories, Inc.
17928690 METHODS AND COMPOSITIONS FOR IN VITRO AFFINITY MATURATION OF MONOCLONAL ANTIBODIES Final Rejection University of Southern California
18464846 COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITY Final Rejection ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
18289740 PARALLEL MULTIPLE DISPLACEMENT AMPLIFICATION METHOD Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18285329 NEXTGEN CHEMOMETRICS USING PROXIMITY LIGATION ASSAY (PLA) Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18695400 COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME Non-Final OA CHUGAI SEIYAKU KABUSHIKI KAISHA
17165293 Affinity Reagent and Catalyst Discovery Through Fiber-Optic Array Scanning Technology Final Rejection SRI International
18282206 SYSTEMS AND METHODS FOR DETERMINING BARCODES AND SCREENING IN SITU Non-Final OA YALE UNIVERSITY
18035678 HAIRPIN OLIGONUCLEOTIDES AND USES THEREOF Final Rejection The University of Chicago

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Amy M Bunker's allowance rate?

29.0% of resolved applications examined by Amy M Bunker were allowed (514 resolved cases), compared with 40.6% across Art Unit 1612 over the last five years.

Does an interview help with examiner Amy M Bunker?

This examiner's interview lift is +45.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Amy M Bunker take to allow a patent?

Applications allowed by Amy M Bunker took 1,427 days on average from filing to allowance.

Which art unit does examiner Amy M Bunker work in?

Amy M Bunker examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month